296 related articles for article (PubMed ID: 34681663)
1. Proteomic Landscape of Extracellular Vesicles for Diffuse Large B-Cell Lymphoma Subtyping.
Carvalho AS; Baeta H; Henriques AFA; Ejtehadifar M; Tranfield EM; Sousa AL; Farinho A; Silva BC; Cabeçadas J; Gameiro P; Silva MGD; Beck HC; Matthiesen R
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681663
[TBL] [Abstract][Full Text] [Related]
2. Extracellular Vesicles in Diffuse Large B Cell Lymphoma: Characterization and Diagnostic Potential.
Matthiesen R; Gameiro P; Henriques A; Bodo C; Moraes MCS; Costa-Silva B; Cabeçadas J; Gomes da Silva M; Beck HC; Carvalho AS
Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362114
[TBL] [Abstract][Full Text] [Related]
3. Platform independent protein-based cell-of-origin subtyping of diffuse large B-cell lymphoma in formalin-fixed paraffin-embedded tissue.
Reinders J; Altenbuchinger M; Limm K; Schwarzfischer P; Scheidt T; Strasser L; Richter J; Szczepanowski M; Huber CG; Klapper W; Spang R; Oefner PJ
Sci Rep; 2020 May; 10(1):7876. PubMed ID: 32398793
[TBL] [Abstract][Full Text] [Related]
4. A super-SILAC based proteomics analysis of diffuse large B-cell lymphoma-NOS patient samples to identify new proteins that discriminate GCB and non-GCB lymphomas.
van der Meeren LE; Kluiver J; Rutgers B; Alsagoor Y; Kluin PM; van den Berg A; Visser L
PLoS One; 2019; 14(10):e0223260. PubMed ID: 31603917
[TBL] [Abstract][Full Text] [Related]
5. Super-SILAC allows classification of diffuse large B-cell lymphoma subtypes by their protein expression profiles.
Deeb SJ; D'Souza RC; Cox J; Schmidt-Supprian M; Mann M
Mol Cell Proteomics; 2012 May; 11(5):77-89. PubMed ID: 22442255
[TBL] [Abstract][Full Text] [Related]
6. Tonic B-cell receptor signaling in diffuse large B-cell lymphoma.
Havranek O; Xu J; Köhrer S; Wang Z; Becker L; Comer JM; Henderson J; Ma W; Man Chun Ma J; Westin JR; Ghosh D; Shinners N; Sun L; Yi AF; Karri AR; Burger JA; Zal T; Davis RE
Blood; 2017 Aug; 130(8):995-1006. PubMed ID: 28646116
[TBL] [Abstract][Full Text] [Related]
7. CD47 Expression Defines Efficacy of Rituximab with CHOP in Non-Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCL.
Bouwstra R; He Y; de Boer J; Kooistra H; Cendrowicz E; Fehrmann RSN; Ammatuna E; Zu Eulenburg C; Nijland M; Huls G; Bremer E; van Meerten T
Cancer Immunol Res; 2019 Oct; 7(10):1663-1671. PubMed ID: 31409608
[TBL] [Abstract][Full Text] [Related]
8. Extracellular vesicles in DLBCL provide abundant clues to aberrant transcriptional programming and genomic alterations.
Rutherford SC; Fachel AA; Li S; Sawh S; Muley A; Ishii J; Saxena A; Dominguez PM; Caldas Lopes E; Agirre X; Chambwe N; Correa F; Jiang Y; Richards KL; Betel D; Shaknovich R
Blood; 2018 Aug; 132(7):e13-e23. PubMed ID: 29967128
[TBL] [Abstract][Full Text] [Related]
9. Differential prognostic impact of GELTAMO-IPI in cell of origin subtypes of Diffuse Large B Cell Lymphoma as defined by the Hans algorithm.
Montalbán C; Díaz-López A; Martín A; Baile M; Sanchez JM; Sancho JM; García O; Novelli S; Monter-Rovira A; Salar A; Bastos M; Gutiérrez A; Bento L; Córdoba R; Arquero T; González de Villambrosia S; Barranco G; De Oña R; López Guillermo A; Rodriguez Salazar MJ; Domínguez JF; Fernández R; Queizan JA; Rodríguez J; Abraira V; García JF;
Br J Haematol; 2018 Aug; 182(4):534-541. PubMed ID: 29978453
[TBL] [Abstract][Full Text] [Related]
10. UCH-L1 is induced in germinal center B cells and identifies patients with aggressive germinal center diffuse large B-cell lymphoma.
Bedekovics T; Hussain S; Feldman AL; Galardy PJ
Blood; 2016 Mar; 127(12):1564-74. PubMed ID: 26702068
[TBL] [Abstract][Full Text] [Related]
11. Dasatinib Is Preferentially Active in the Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma.
Cann ML; Herring LE; Haar LL; Gilbert TSK; Goldfarb D; Richards KL; Graves LM; Lawrence DS
J Proteome Res; 2019 Jan; 18(1):522-534. PubMed ID: 30540191
[TBL] [Abstract][Full Text] [Related]
12. Proteomic dissection of large extracellular vesicle surfaceome unravels interactive surface platform.
Rai A; Fang H; Claridge B; Simpson RJ; Greening DW
J Extracell Vesicles; 2021 Nov; 10(13):e12164. PubMed ID: 34817906
[TBL] [Abstract][Full Text] [Related]
13. BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab.
Iqbal J; Meyer PN; Smith LM; Johnson NA; Vose JM; Greiner TC; Connors JM; Staudt LM; Rimsza L; Jaffe E; Rosenwald A; Ott G; Delabie J; Campo E; Braziel RM; Cook JR; Tubbs RR; Gascoyne RD; Armitage JO; Weisenburger DD; Chan WC
Clin Cancer Res; 2011 Dec; 17(24):7785-95. PubMed ID: 21933893
[TBL] [Abstract][Full Text] [Related]
14. Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.
Xu-Monette ZY; Li L; Byrd JC; Jabbar KJ; Manyam GC; Maria de Winde C; van den Brand M; Tzankov A; Visco C; Wang J; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Wang M; Hagemeister FB; Piris MA; Han van Krieken J; Medeiros LJ; Li Y; van Spriel AB; Young KH
Blood; 2016 Dec; 128(26):3083-3100. PubMed ID: 27760757
[TBL] [Abstract][Full Text] [Related]
15. Prediction and characterization of diffuse large B-cell lymphoma cell-of-origin subtypes using targeted sequencing.
Trabucco SE; Sokol ES; Maund SL; Moore JA; Frampton GM; Albacker LA; Oestergaard MZ; Venstrom J; Sehn LH; Bolen CR
Future Oncol; 2021 Nov; 17(31):4171-4183. PubMed ID: 34313135
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical distinction of ABC and GCB in extranodal DLBCL is not reflected in mutation patterns.
Hallas C; Preukschas M; Tiemann M
Leuk Res; 2019 Jan; 76():107-111. PubMed ID: 30360939
[TBL] [Abstract][Full Text] [Related]
17. Quantitative proteomics analysis of differentially expressed proteins in activated B-cell-like diffuse large B-cell lymphoma using quantitative proteomics.
Gao HX; Nuerlan A; Abulajiang G; Cui WL; Xue J; Sang W; Li SJ; Niu J; Ma ZP; Zhang W; Li XX
Pathol Res Pract; 2019 Sep; 215(9):152528. PubMed ID: 31324389
[TBL] [Abstract][Full Text] [Related]
18. Application of CD54 in diagnosing bone marrow involvement by using flow cytometry in patients with diffuse large B-cell lymphoma.
Wang W; Li Y; Rivera Rivera X; Zhao L; Mei D; Hu W; Jiang B
BMC Cancer; 2021 Sep; 21(1):1011. PubMed ID: 34503477
[TBL] [Abstract][Full Text] [Related]
19. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma.
Dunleavy K; Pittaluga S; Czuczman MS; Dave SS; Wright G; Grant N; Shovlin M; Jaffe ES; Janik JE; Staudt LM; Wilson WH
Blood; 2009 Jun; 113(24):6069-76. PubMed ID: 19380866
[TBL] [Abstract][Full Text] [Related]
20. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
Fu K; Weisenburger DD; Choi WW; Perry KD; Smith LM; Shi X; Hans CP; Greiner TC; Bierman PJ; Bociek RG; Armitage JO; Chan WC; Vose JM
J Clin Oncol; 2008 Oct; 26(28):4587-94. PubMed ID: 18662967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]